Reference

Composition comprising combination of cannabinoid receptor-1 antagonist and DPP-IV inhibitor

All Rights Reserved. Composition comprising combination of cannabinoid receptor-1 antagonist and DPP-IV inhibitor.Several substances are used for example 168273-06-1 and 183232-66-8 which are their cas registry numbers. Milosavljevic-Ristic, Smiljana (Novartis A.-G.; Novartis Pharma G.m.b.H., Switz.). PCT Int. Appl. WO 2007006790 A2 18 Jan 2007, 49pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: A61K. APPLICATION: WO 2006-EP64117 11 Jul 2006. PRIORITY: US 2005-698304P 12 Jul 2005. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 1 The present invention relates to a combination, such as a combined prepn. or pharmaceutical compn., resp., comprising of a DPP IV inhibitor or a pharmaceutically acceptable salt thereof and comprising at least one CB1 antagonist, or a pharmaceutically acceptable salt thereof. The present invention furthermore relates to the use of such a combination for the prevention of, delay of progression of, treatment of diseases and disorders that may be inhibited by DPP IV inhibition, appetency disorders or substance abuse disorders. Thus, combination of vildagliptin 50 mg and rimionabant 20 mg was used for improvement of cognitive function. .

Dosing regimen of CB1 receptor antagonists for weight loss

All Rights Reserved. Dosing regimen of CB1 receptor antagonists for weight loss. Koopmans, Henry Sjoerd; Sharkey, Keith Alexander; Chambers, Adam Paul (UTI Limited Partnership, Can.Chemicals with cas numbers 168273-06-1 and 183232-66-8 also play role.). PCT Int. Appl. WO 2007016771 A1 15 Feb 2007, 55pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. APPLICATION: WO 2006-CA1284 4 Aug 2006. PRIORITY: US 2005-595791P 5 Aug 2005; CA 2005-2518579 8 Sep 2005. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) Section cross-reference(s): 63 The invention discloses dosing regimens and methods for the treatment of obesity, overweight and/or overeating in mammals, comprising administering to the mammal a pharmaceutically effective amt. of a CB1 receptor antagonist as a unit dosage according to a continuous schedule having a dosing interval selected from the group consisting of once-weekly dosing, twice-weekly dosing, thrice-weekly dosing, biweekly and bimonthly. .